Log in
NASDAQ:VERU

Veru Stock Forecast, Price & News

$2.87
-0.01 (-0.35 %)
(As of 09/18/2020 09:42 PM ET)
Add
Compare
Today's Range
$2.81
Now: $2.87
$3.02
50-Day Range
$2.62
MA: $2.81
$3.19
52-Week Range
$1.85
Now: $2.87
$4.74
Volume1.55 million shs
Average Volume548,005 shs
Market Capitalization$200.51 million
P/E RatioN/A
Dividend YieldN/A
Beta0.14
Veru Inc. operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation. The company's urology drug candidates include Tamsulosin delayed release sachet and Tamsulosin XR capsules that are under bioequivalence study for the treatment of benign prostatic hyperplasia; and Solifenacin delayed release granules, which is under bioequivalence study for the treatment of overactive bladder. Its urology drug candidates also comprise Tadalafil and Finasteride combination capsules that are under bioequivalence study for the treatment of men with lower urinary tract symptoms and enlarged prostate. The company's oncology drug candidate includes VERU-944, which is in Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and VERU-111, an oral alpha and beta tubulin inhibitor, which is under Phase 1b/2 study for the treatment of metastatic prostate, breast, endometrial, ovarian, and pancreatic cancers. It serves agencies, health care distributors, non-government organizations, ministries of health, and other governmental agencies through distributors and retailers primarily in the United States, Brazil, Spain, France, and the United Kingdom. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was founded in 1896 and is headquartered in Miami, Florida.
Read More
Veru logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.88 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPersonal Products
SectorMedical
Current SymbolNASDAQ:VERU
CUSIP31446210
Phone305-509-6897

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$31.80 million
Book Value$0.50 per share

Profitability

Net Income$-12,020,000.00

Miscellaneous

Employees171
Market Cap$200.51 million
Next Earnings Date12/10/2020 (Estimated)
OptionableOptionable
$2.87
-0.01 (-0.35 %)
(As of 09/18/2020 09:42 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VERU News and Ratings via Email

Sign-up to receive the latest news and ratings for VERU and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Veru (NASDAQ:VERU) Frequently Asked Questions

How has Veru's stock been impacted by Coronavirus?

Veru's stock was trading at $3.20 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, VERU shares have decreased by 10.3% and is now trading at $2.87.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Veru?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veru in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Veru
.

When is Veru's next earnings date?

Veru is scheduled to release its next quarterly earnings announcement on Thursday, December 10th 2020.
View our earnings forecast for Veru
.

How were Veru's earnings last quarter?

Veru Inc (NASDAQ:VERU) posted its quarterly earnings data on Thursday, August, 13th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by $0.02. The company earned $10.32 million during the quarter, compared to the consensus estimate of $10.68 million. Veru had a negative net margin of 25.78% and a negative return on equity of 30.37%.
View Veru's earnings history
.

What price target have analysts set for VERU?

3 brokers have issued 1-year target prices for Veru's shares. Their forecasts range from $6.00 to $9.00. On average, they anticipate Veru's share price to reach $7.50 in the next twelve months. This suggests a possible upside of 161.3% from the stock's current price.
View analysts' price targets for Veru
.

Are investors shorting Veru?

Veru saw a increase in short interest in August. As of August 31st, there was short interest totaling 2,000,000 shares, an increase of 24.2% from the August 15th total of 1,610,000 shares. Based on an average trading volume of 817,000 shares, the short-interest ratio is currently 2.4 days. Currently, 3.7% of the shares of the stock are short sold.
View Veru's Short Interest
.

Who are some of Veru's key competitors?

What other stocks do shareholders of Veru own?

Who are Veru's key executives?

Veru's management team includes the following people:
  • Dr. Mitchell S. Steiner M.D., F.A.C.S, Chairman, Pres & CEO (Age 58)
  • Dr. Harry Fisch, Vice Chairman & Chief Corp. Officer (Age 60)
  • Mr. O. B. Parrish, Co-Founder & Director (Age 86)
  • Ms. Michele Greco, CFO, Exec. VP of Fin. & Chief Admin. Officer (Age 60)
  • Dr. K. Gary Barnette Ph.D., Chief Scientific Officer (Age 51)

What is Veru's stock symbol?

Veru trades on the NASDAQ under the ticker symbol "VERU."

Who are Veru's major shareholders?

Veru's stock is owned by many different retail and institutional investors. Top institutional shareholders include AWM Investment Company Inc. (0.59%), Wedge Capital Management L L P NC (0.43%), Nuveen Asset Management LLC (0.34%), EAM Investors LLC (0.23%), Two Sigma Advisers LP (0.19%) and Bank of New York Mellon Corp (0.20%). Company insiders that own Veru stock include Harry Fisch, Jesus Socorro, K Gary Barnette, Michele Greco and Mitchell Shuster Steiner.
View institutional ownership trends for Veru
.

Which major investors are selling Veru stock?

VERU stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., EAM Investors LLC, AWM Investment Company Inc., Bank of America Corp DE, Wedge Capital Management L L P NC, and Engineers Gate Manager LP.
View insider buying and selling activity for Veru
.

Which major investors are buying Veru stock?

VERU stock was bought by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Bank of New York Mellon Corp, Charles Schwab Investment Management Inc., Two Sigma Advisers LP, New York State Common Retirement Fund, American International Group Inc., SG Americas Securities LLC, and HighTower Advisors LLC. Company insiders that have bought Veru stock in the last two years include Harry Fisch, Jesus Socorro, K Gary Barnette, and Michele Greco.
View insider buying and selling activity for Veru
.

How do I buy shares of Veru?

Shares of VERU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Veru's stock price today?

One share of VERU stock can currently be purchased for approximately $2.87.

How big of a company is Veru?

Veru has a market capitalization of $200.51 million and generates $31.80 million in revenue each year. The company earns $-12,020,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. Veru employs 171 workers across the globe.

What is Veru's official website?

The official website for Veru is www.veruhealthcare.com.

How can I contact Veru?

Veru's mailing address is 48 NW 25th Street Suite 102, Miami FL, 33127. The company can be reached via phone at 305-509-6897 or via email at [email protected]

This page was last updated on 9/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.